Women drive Arkansas GLP-1 weight-loss surge
Women are being prescribed GLP-1 weight-loss drugs at higher rates than men, new data shows.
Why it matters: This is another cultural moment when women, especially those approaching menopause, are paying more for their well-being.
Between the lines: GLP-1 drugs like Ozempic and Mounjaro are usually covered by insurance when used to treat Type 2 diabetes — but many doctors also prescribe them off-label for overweight and obesity, which often isn't covered.
Zoom in: In Arkansas, women have been prescribed GLP-1 drugs at higher rates than men since 2020, and the rate of women prescribed the drug has more rapidly increased, according to 2024 data from FAIR Health.
The fine print: The data reflects insured adults who received medical care nationally, but doesn't include people buying non-FDA-approved versions of the drugs from compounding pharmacies.
The big picture: Nationally, 18.6% of women prescribed GLP-1 drugs received them for weight loss (and not diabetes) — double the rate of men, at 9.3% — according to FAIR Health.
Women between 40 and 64 have been the top recipients of GLP-1 prescriptions since 2019. For men, the top users in most years have been seniors.
What we're hearing:"In my experience, thus far, it's been entirely women" — many of them approaching menopause — who ask to be on GLP-1 drugs to lose weight, says family physician Beth Oller, who practices in rural Kansas.
At a certain age, "the things you used to do for weight loss aren't cutting it anymore," says Oller, who's 45 and tells Axios she has firsthand experience with this.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
2 hours ago
- New York Times
Is It Wrong to Push Ozempic on My Spouse?
My husband's lifestyle is very sedentary, with minimal exercise (20 to 60 minutes a week), though he does eat a largely healthy diet. I've watched him struggle with his weight over the 15 years we've been together, cycling through various approaches to diet and exercise. Even when he succeeds in losing weight, it always comes back, and now he seems to have given up. As we both approach 50, I worry that his B.M.I., which is 30, and his B.R.I. (body roundness index, a measure of abdominal fat) are high (he can't even button some of his shirts around the middle), which could lead to other health issues. I've already tried encouraging him to move more and eat better, but I can't schedule every one of my workouts for us to exercise together, and he dislikes some of the routines I do, anyway. He's also very sensitive about his weight. Is it wrong for me to try to get him to take Ozempic? I'm hoping that losing weight will help boost his energy levels, which might lead to more self-care. I know it's not my body, and I'm not his doctor, but as his wife I also know it will fall to me to care for him if health issues arise. — Name Withheld From the Ethicist: It's natural to worry about the health of someone you love — especially as the years accumulate and the lines between caring for yourself and caring for your partner begin to blur. Long-term relationships involve a particular kind of vigilance: You notice the wince, the shortened breath, the unbuttoned shirt. This isn't control; it's love in the form of everyday attention. Obesity really is correlated with health problems, and if your husband could lose weight sustainably, his life might improve in ways that matter. Historically, weight loss has been a story of perpetual disappointment — diets abandoned, exercise routines that peter out, New Year's resolutions that start wobbling the following evening when it becomes clear that celery sticks are an imperfect substitute for chocolates. GLP-1 drugs, such as Ozempic, have helped many people break that cycle. Still, even sound advice can land wrong if it touches a nerve. If your husband is sensitive about his weight, the real challenge isn't knowing what's best; it's finding a way to talk about it that feels loving, not critical. Try to keep the focus on the prospect of his feeling fitter and on your hope for more good years ahead. Maybe suggest he talk to his doctor — not as a directive but as a way to explore options. You're not pushing him to 'fix' himself; you're looking out for him. If it turns out to be a difficult conversation all the same? Loving someone can mean risking that discomfort — for the sake of all the days you haven't yet lived together. Want all of The Times? Subscribe.
Business Upturn
3 hours ago
- Business Upturn
Rainbow Children's Medicare acquires majority stake in Prashanthi Hospital
By Aman Shukla Published on June 28, 2025, 14:30 IST Rainbow Children's Medicare Limited (RCML) has announced the acquisition of a majority stake in Prashanthi Medicare Private Limited, a reputed 100-bed NABH-accredited hospital in Warangal, Telangana. The acquisition marks a strategic expansion into tier-II cities and enhances RCML's presence in southern India. Established in 2015 by Dr. Prasanthi Macha, Prashanthi Hospital is recognized for excellence in obstetrics, gynecology, neonatology, pediatrics, and minimally invasive surgery. The hospital has built a strong regional reputation and continues to serve as a trusted destination for maternal and child healthcare in Warangal, Telangana's second-largest district. With this acquisition, RCML's total bed capacity increases to 2,035 across 20 hospitals in seven cities. The transaction, valued at approximately ₹32.60 crore (subject to working capital adjustments), is based on 9x estimated FY25 adjusted EBITDA and will be funded through internal accruals and cash reserves. RCML will acquire a 76% equity stake and 100% of the Non-convertible Redeemable Preference Shares (NCRPS), while Dr. Macha and associates will retain a 24% minority stake. Post-acquisition, the facility will operate under a dual brand: Rainbow Children's Hospital for pediatric services and Prashanthi with BirthRight for women's health services. The integration will support RCML's hub-and-spoke model, ensuring efficient referrals and clinical alignment with its Hyderabad tertiary care hub. Ahmedabad Plane Crash Rainbow Children's Medicare Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
4 hours ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
